Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05007769
Title Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC (RAN)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Washington University School of Medicine
Indications
Therapies
Age Groups: adult | senior
Covered Countries

Facility Status City State Zip Country Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field